Bispecifics in Multiple Myeloma: Patient Journey and Clinical Insights

home / from-all-angles / bispecifics-in-multiple-myeloma-patient-journey-and-clinical-insights

Binod Dhakal, MD, MS, and Karen Kehl discuss how bispecific antibody therapy with talquetamab has transformed the treatment journey for a multiple myeloma patient who achieved durable responses after 19-plus prior treatments, exploring the drug's mechanism targeting GPRC5D, clinical trial data showing 70% response rates, practical considerations including step-up dosing strategies and manageable adverse effects like taste changes and nail issues, and the patient's positive quality of life outcomes that have allowed her to continue living actively 16 years post diagnosis.

1 expert is featured in this series.

EP. 1: Karen's Story: Navigating Multiple Myeloma Treatment Lines

Binod Dhakal, MD, MS
July 30th 2025

Panelists discuss how multiple myeloma patients navigate complex treatment journeys through multiple relapses, clinical trials, and the transformative potential of bispecific antibody therapies like talquetamab, with patient Karen Kehl sharing her 15-year experience from initial diagnosis through 19 treatment cycles including three transplants and various clinical trials.

1 expert is featured in this series.

EP. 2: Understanding Bispecific Mechanisms and Dual Targeting in Multiple Myeloma: Why talquetamab for This Patient Journey

Binod Dhakal, MD, MS
July 30th 2025

Panelists discuss how bispecific antibodies like talquetamab work through dual targeting mechanisms that bring T-cells and cancer cells together for tumor destruction, with patient Karen sharing her decision-making process based on treatment convenience, manageable adverse effects like taste loss and nail changes, and the therapy's effectiveness after initial severe reactions during step-up dosing.